Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5874-5880

  Cass, Robert T ^a   Brooks, Carter D ^b   Havrilla, Nancy A ^c   Tack, Kenneth J ^a   Borin, Marie T ^a   Young, Don ^a   Bruss, Jon B ^d  

^a Achaogen Inc   (United States)

^b Jasper Clinic Inc   (United States)

^c Ardea Biosciences Inc   (United States)

^d Medpace ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACHN 490; AMINOGLYCOSIDE ANTIBIOTIC AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COCHLEA; COHORT ANALYSIS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HEADACHE; HUMAN; HYPEREMIA; HYPESTHESIA; KIDNEY FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NOSE CONGESTION; ORAL PARESTHESIA; PALLOR; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; STEADY STATE; T WAVE; TACHYCARDIA; TREATMENT DURATION; VESTIBULAR FUNCTION; XEROSTOMIA;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; SISOMICIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81555206664     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00624-11     Document Type: Article

References (22)

1. Aggen, J. B., et al. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother. 54:4636-4642.
2. Ambrose, P. G., et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. (Pubitemid 44968990)
3. Armstrong, E. S., and G. H. Miller. 2010. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr. Opin. Microbiol. 13:566-573.
4. Bastone, E. B., S. C. Li, L. L. Ioannides-Demos, W. J. Spicer, and A. J. McLean. 1993. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob. Agents Chemother. 37:914-917. (Pubitemid 23096905)
5. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060. (Pubitemid 17099578)
6. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
7. Drusano, G. L., et al. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760. (Pubitemid 47378891)
8. Durante-Mangoni, E., A. Grammatikos, R. Urili, and M. E. Falagas. 2009. Do we still need the aminoglycosides? Int. J. Antimicrob. Agents 33:201-205.
9. Endimiani, A., et al. 2009. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53:4504-4507.
10. Golden, G. S., L. H. Golden, and F. R. Beerel. 1975. Hyperventilation- induced T-wave changes in the limb lead electrocardiogram. Chest 67:123-125.
11. Kozak, A. J., D. N. Gerding, L. R. Peterson, and W. H. Hall. 1977. Gentamicin intravenous infusion rate: effect on interstitial fluid concentration. Antimicrob. Agents Chemother. 12:606-608. (Pubitemid 8209360)
12. Landman, D., et al. 2010. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J. Antimicrob. Chemother. 65:2123-2127.
13. Landman, D. E., et al. 2011. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J. Antimicrob. Chemother. 66:332-334.
14. Lin, G., L. M. Ednie, and P. C. Appelbaum. 2010. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob. Agents Chemother. 54:2258-2261.
15. Moore, R. D., P. D. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99. (Pubitemid 17225088)
16. Nicolau, D. P., et al. 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39:650-655.
17. Radigan, E. A., N. A. Gilchrist, and M. A. Miller. 2010. Analytic reviews: management of aminoglycosides in the intensive care unit. J. Intensive Care Med. 25:327-342.
18. Reyes, N., J. B. Aggen, and C. F. Kostrub. 2011. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob. Agents Chemother. 55:1728-1733.
19. Rybak, M. J., et al. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555. (Pubitemid 29331226)
20. Staneva, M., B. Markova, I. Atanasova, and D. Terziivanov. 1994. Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin. Antimicrob. Agents Chemother. 38:981-985. (Pubitemid 24150825)
21. Van Wart, S., et al. 2010. Population pharmacokinetics of ACHN-490 injection in healthy subjects. Abstr. 48th Annu. Meet. Infect. Dis. Soc. Am., poster 209.
22. Zelenitsky, S. A., G. K. Harding, S. Sun, K. Ubhi, and R. E. Ariano. 2003. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J. Antimicrob. Chemother. 52:668-674. (Pubitemid 37258430)